Orchestra BioMed develops therapeutic devices and drug-device combination products targeting large unmet needs in procedure-based cardiovascular medicine. It advances its pipeline through strategic partnerships with established medical device companies that handle global commercialization under risk-reward sharing arrangements. Notable collaborations include AVIM neuromodulation therapy for hypertension with Medtronic and the Virtue drug-coated balloon platform with Terumo.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0.8 | — | -19.4 | — |
| Q3 2025 | 0.9 | — | -20.8 | — |
| Q4 2025 | 30.9 | — | 6 | — |
| Q1 2026 | 0.1 | — | -20.7 | — |
| Q2 2026 | 0.1 | -89.5% | -24.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: PrimeEnergy Resources Corporation (PNRG), TWFG, Inc. (TWFG), JAKKS Pacific, Inc. (JAKK), Cal Redwood Acquisition Corp. (CRAQ), Renatus Tactical Acquisition Corp I (RTAC), Xerox Holdings Corporation (XRX)